PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens

BOMBSHELL: FDA MUST HAVE KNOWN THAT MYOCARDITIS IN TEENS WAS A RISK WHEN THEY ISSUED THE EMERGENCY USE AUTHORIZATION THAT DID NOT MENTION IT.

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens Screen-Shot-2022-04-04-at-2.22.50-PM-4-212x300

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens Screen-Shot-2022-04-04-at-2.22.50-PM-4-212x300

In a paper published in pre-print last week (25th March, 2022) in the Journal of Pediatrics .https://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext#%20 Shauer et al. from the Seattle Children’s Hospital at the University of Washington:
Report on their findings of 35 cases of myocarditis in children within one week after receiving the second dose of the Pfizer mRNA vaccine.

They present the evolution of changes on Cardiac MRI (Magnetic Resonance Imaging)

1) Myopericarditis has emerged as an important adverse event following COVID-19 mRNA vaccination, particularly in adolescents. This affects both the lining of the heart (pericardium) and the cardiac muscle (myocardium) itself.

[Ref: Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Morbidity and Mortality Weekly Report Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices-United States, June 2021 .https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312754/

The report acknowledged the risks of myocarditis post vaccine, but still recommended vaccination to everyone.

This initial report, established the serious problem of myopericarditis in adolescents following MRNA vaccination was published in June 2021.

June 2021 was one month AFTER the FDA received the priority review for an EUA for 16 yrs and older to receive the mRNA vaccine.

2) This timeline raises grave questions about what the FDA knew and when they knew it, since the results of this paper would have been ‘peer reviewed’ some months BEFORE the May 2021 publication took place.

That is, the risk of heart damage to teenagers would have been part of the medical knowledge base BEFORE the emergency use authorization for teenagers was issued by the FDA in June 2021.

The finding of heart damage in teenagers, thus, would have been available to the FDA at the time of the May 2021 EUA application.

The FDA did not disclose the risk of these harms to the general public at that time.

3) The Emergency Use Authorization itself in May 2021 does NOT mention any risk of myocarditis in adolescents, even though the 16+ age group was being filed for in this EUA.

An FDA committee reviews and then grants the EUA. The FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) met to discuss newly available data for the currently available COVID-19 vaccines

We [the volunteers in the Pfizer WarRoom documents review group Team 3] have not seen any discussions of the issues [of myopericarditis] by the FDA approvals committee as they are not available to the public.

There is no press release from the FDA about the approval of the May 2021 EUA application, but in an August 2021 press release .https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine the FDA report that myocarditis is a known side effect and a warning is in the data sheet of the newly authorized commercial vaccine (Comirnarty).

.https://dailyclout.io/pfizer-vaccine-fda-fails-to-mention-risk-of-heart-damage-in-teens/

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens 4QXsKnR

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens 4QXsKnR

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens

PFIZER VACCINE: FDA Fails to Mention Risk of Heart Damage in Teens

Anarcho-Capitalist Categorical Imperatives

AnCaps In Science, Technology & Environment